Literature DB >> 30097464

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels.

Ayalew Tefferi1, Maura Nicolosi1, Domenico Penna1, Mythri Mudireddy1, Natasha Szuber1, Terra L Lasho1, Curtis A Hanson2, Rhett P Ketterling3, Naseema Gangat1, Animesh D Pardanani1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30097464      PMCID: PMC6093731          DOI: 10.1182/bloodadvances.2018018051

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  14 in total

Review 1.  Biomarkers of cancer cachexia.

Authors:  Audrey Loumaye; Jean-Paul Thissen
Journal:  Clin Biochem       Date:  2017-07-21       Impact factor: 3.281

2.  Low-density lipoprotein (LDL) distribution shown by 99mtechnetium-LDL imaging in patients with myeloproliferative diseases.

Authors:  S Vallabhajosula; H S Gilbert; S J Goldsmith; M Paidi; M M Hanna; H N Ginsberg
Journal:  Ann Intern Med       Date:  1989-02-01       Impact factor: 25.391

Review 3.  Metabolic Changes During Cancer Cachexia Pathogenesis.

Authors:  Ng Shyh-Chang
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

4.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

5.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

6.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

7.  Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia.

Authors:  D A Brenner; M Buck; S P Feitelberg; M Chojkier
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis.

Authors:  Marko Lucijanic; Ivo Veletic; Dario Rahelic; Vlatko Pejsa; David Cicic; Marko Skelin; Ana Livun; Katarina Marija Tupek; Tajana Stoos-Veic; Tomo Lucijanic; Ana Maglicic; Rajko Kusec
Journal:  Wien Klin Wochenschr       Date:  2018-01-25       Impact factor: 1.704

Review 9.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

10.  Increased low-density-lipoprotein catabolism in myeloproliferative disorders.

Authors:  H Ginsberg; H S Gilbert; J C Gibson; N A Le; W V Brown
Journal:  Ann Intern Med       Date:  1982-03       Impact factor: 25.391

View more
  4 in total

1.  Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models.

Authors:  Elisabetta De Marinis; Alessia Ceccherelli; Alberto Quattrocchi; Loris Leboffe; Fabio Polticelli; Clara Nervi; Paolo Ascenzi
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

2.  Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms.

Authors:  Tetsuro Yokokawa; Tomofumi Misaka; Yusuke Kimishima; Kento Wada; Keiji Minakawa; Koichi Sugimoto; Takafumi Ishida; Soji Morishita; Norio Komatsu; Kazuhiko Ikeda; Yasuchika Takeishi
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

3.  Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.

Authors:  Yang Tang; Wenli Liu; Wei Wang; Trevor Fidler; Britany Woods; Ross L Levine; Alan R Tall; Nan Wang
Journal:  Cardiovasc Drugs Ther       Date:  2020-04       Impact factor: 3.727

4.  The Relationship Between Hematological Malignancy and Lipid Profile.

Authors:  Erman Ozturk
Journal:  Medeni Med J       Date:  2021-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.